Cell Surface Markers Market

Global Cell Surface Markers Market Size (2023 to 2028)

The global cell surface markers market size is predicted to expand at a CAGR of 8.12% from 2023 to 2028 and be worth USD 1052.9 million by 2028 from USD 712.61 million in 2023.

Protein or antigenic determinants located on the surface of various types of cells are known as cell surface markers. They also serve as a marker for determining the cell type. In addition, cell surface marker analysis is used to determine ligands or drug responses in research activities. End-use verticals and companies concentrate on CD markers, t cell surface markers, the cluster of differentiation in immunology, t cell markers flow cytometry, T cell marker immunohistochemistry, T cell immunophenotyping, cell membrane, lymphocyte markers, a cluster of differentiation, and others. The percentage of lymphocytes and the absolute number of lymphocytes are examples of constant innovation.

MARKET DRIVERS:

The growing demand for precision medicine is one of the major factors propelling the growth of the cell surface markers market.

The adoption of precision medicine is growing rapidly worldwide. Precision medicine differs from traditional medicine and is more effective in treating diseases. Cell surface markers play a vital role in the development of precision medicine as it allows researchers to identify specific target cells or biomarkers associated with diseases. For example, cell surface markers are used to identify specific types of cancer cells and later researchers use this information to develop target therapies that can show a significant impact on the cancer cells. In the coming years, the demand for precision medicine is predicted to grow significantly due to factors such as the increasing patient population suffering from chronic diseases and the rapid adoption of technological developments in precision medicine, which is expected to boost the demand for cell surface markers and contribute to the market’s growth rate.

In addition, increasing usage of advanced diagnostics and technological advancements of throughput and automation fuel the global cell surface markers market growth.  As a result of continued efforts to reduce disease and healthcare burdens, the global market is expected to grow due to the increased usage of advanced analytical technologies and in-vitro diagnostic instruments. The growing use of stem cell technology and initiatives to lower the cost of disease diagnostics is another key factor supporting the market's growth rate. New therapeutics that target liver cancer stem cells are likely to increase the overall efficacy of standard radiation and chemotherapy treatments for liver cancer.

Furthermore, the growing funding for life sciences research, a high global prevalence of cancer, and expansion in stem cell and neurobiology research are favoring the growth rate of the cell surface marker market. Advanced laboratory equipment such as flow cytometers can easily aid in rapidly detecting severe medical diseases. The availability of high-end and faster cell sorting and cell analysis solutions in flow cytometers for research and clinical development makes point-of-care diagnosis more accessible by automating sample processing and allowing high throughput screening, which is expected to support the cell surface marker market growth during the forecast period.

MARKET RESTRAINTS:

However, high costs associated with cell surface marker services are one of the major factors hampering the growth of the market. Small pharmaceutical companies are increasingly hesitant to invest in highly complex flow cytometers and hematological analyzers due to the unclear cost-benefit relationship. Furthermore, because drug development is expensive, smaller pharmaceutical companies cannot afford to invest in pricey equipment and consumables, which is expected to limit the market’s growth rate during the forecast period. Furthermore, the complicated products, expensive instruments, and reagents utilized in cell marker analysis hinder market growth.

Impact of COVID-19 on the cell surface markers market:

The COVID-19 pandemic had a significant impact on the cell surface markers market. Cell surface markers are carbohydrates and proteins linked to the cell membrane, allowing them to play an essential role in intercellular signaling. The interaction of COVID-19 antibodies with cell surface indicators is the subject of numerous research initiatives. Due to their decreased immunity, many COVID-19 patients see an upsurge in secondary fungal infections. As a result, those cell surface markers are expected to research fungal infection to improve growth. In addition, such activities help enhance understanding of the disease and develop new methods to find a cure. More research initiatives using cell surface markers to examine the effect of COVID-19 are being undertaken worldwide. As a result, such innovations are projected to support market growth.

REPORT COVERAGE:

This research report on the global cell surface markers market has been segmented and sub-segmented based on source, cell type, end-user & region.

Cell Surface Markers Market – By Type:

• T Cell Surface Markers
• NK Cell Surface Markers
• B Cell Surface Markers
• Monocyte Cell Surface Markers

Based on type, the T cell surface marker segment is expected to have the major share of the worldwide market during the forecast period owing to the growing usage of t cell surface markers in research and diagnostic applications. In addition, the ability of T cell surface markers in cell multiplication and activation during infections and their efficacy in detecting antigens delivered into the body through histocompatibility and complex aid in infection detection is further fuelling segmental growth. Furthermore, the growing number of infections and the number of scientific studies undertaken in this field are propelling segmental growth.

Cell Surface Markers Market – By End-User:

• Clinical Testing Laboratories & Hospitals
• Academic & Research Institutes
• Biotechnology & Pharmaceutical Companies

Based on end-user, the academic and research institutes segment is estimated to account for the largest global cell surface markers market share during the forecast period. The segment's growth is majorly driven by the growing usage of cell surface markers in the research and development of treatment procedures for diseases such as cancer, stem cell, and HIV. In addition, an increasing number of collaborations between the market participants and academic and research activities to conduct R&D around cell surface markers and growing funding by the governmental and non-governmental organizations in favor of cell surface markers are further fuelling the segment’s growth rate.

Cell Surface Markers Market – By Source:

• Rats
• Mice
• Others

Based on source, the mice segment held the major share of the global cell surface markers market in 2022 and the segmental domination is anticipated to continue throughout the forecast period. The growth of the segment is primarily driven by the cost-effectiveness of mice models as a source of antibody production. The mice segment is also predicted to witness the fastest CAGR during the forecast period.

Cell Surface Markers Market – By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

The North American cell surface markers market accounted for the most significant share of the worldwide market in 2022 and is expected to continue playing the dominating role in the global market throughout the forecast period. The growing usage of cell surface markers in the treatment procedures of various diseases, rapidly growing pharmaceutical and biotechnology industries and the presence of numerous pharmaceutical, biotechnological, academic and research institutes that operate with cell surface markers are majorly driving the North American market growth. In 2022, the U.S. market occupied the major share of the North American market, followed by Canada. The U.S. cell surface markers market is also expected to witness a healthy CAGR during the forecast period owing to the increasing healthcare spending, growing adoption of technological developments in the healthcare industry, and rising emphasis on precise diagnosis are fuelling the market growth in the U.S. The presence of key market participants and an increasing number of R&D activities by the market participants are further boosting the U.S. market growth. The growing usage of cell surface markers in personalized medicine and drug discovery in the U.S. is another notable factor supporting the U.S. market growth. The increasing patient population suffering from chronic diseases like cancer and the growing need for effective diagnostic procedures favor the U.S. cell surface markers market.

The European cell surface markers market ranked as the second biggest regional market worldwide in 2022 and is estimated is register strong growth during the forecast period. The growth of the European market is driven by the growing patient count suffering from cancer and autoimmune diseases, increasing adoption of personalized medicine and rising research and development activities around new and innovative technologies for cell analysis and isolation. Companies such as BD Biosciences, Bio-Rad Laboratories, Thermo Fisher Scientific, Beckman Coulter, and Miltenyi Biotec play a significant role in the European cell surface markers market.

During the forecast period, the market in Asia Pacific is expected to be lucrative and grow at the fastest CAGR. The growth of the APAC market is majorly driven by increasing R&D activities in the life sciences industry efforts and favorable initiatives by the governments of APAC countries to strengthen the biotechnology and pharmaceutical industries. In addition, the growing aging population, rising adoption of technological developments, increasing demand for advanced treatment procedures for chronic diseases and growing adoption of early disease detection by the population of APAC countries are driving the cell surface markers market growth in the Asia-Pacific region. During the forecast period, India, China and Japan are predicted to hold the major share of the APAC market.

The Latin American cell surface marker market is predicted to account for a considerable share of the worldwide market during the forecast period. Increasing investments in R&D activities in the Latin American region, growing demand for advanced diagnostics and rapid adoption of personalized medicine by healthcare providers are driving the Latin American cell surface markers market. Brazil, Mexico, Argentina, and Chile held the largest share of the Latin American market in 2022 and the same trend is expected to repeat during the forecast period.

The cell surface markers market in MEA is expected to showcase a moderate CAGR in the coming years. The growing patient population suffering from chronic diseases is accelerating the MEA market. The growing adoption of advanced technologies in research and diagnostics applications and increasing demand for targeted therapies are further contributing to the growth of the MEA market. Countries such as Saudi Arabia, UAE, Egypt, and South Africa are predicted to control a major share of the MEA market in the coming years.

KEY MARKET PLAYERS:

Bio-Rad Laboratories, Inc., Siemens Healthcare Private Limited, Beckman Coulter, Inc., NIHON KOHDEN CORPORATION, Hoffmann-La Roche Ltd, BD, Abcam PLC., QIAGEN, Thermo Fisher Scientific, Abbott, Danaher, GenScript, Merk KGaA, BioLegend, Inc. and Cell Signaling Technology, Inc. are a few of the prominent companies operating in the global cell surface markers market profiled in this report.

RECENT MARKET DEVELOPMENTS:

• Becton, Dickinson, and Company announced in October 2020 that the BD FACSLyric Flow Cytometer with the integrated BD FACSDuet Sample Preparation System had achieved 510(k) clearance from the US Food and Drug Administration (FDA).
• Beckman Coulter will offer the DxH 690T hematology analyzer in the United States in May 2020, with improved capabilities for mid-volume facilities such as the Early Sepsis Indicator.
• Sysmex America Inc. announced the launch of its XF-1600 flow cytometer in June 2020, giving laboratories greater flexibility and efficiency for various applications.